Loading
A phase 2 trial of Pafolacianine in Oesophageal cancer, run by John Waters, now recruiting.
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer is a phase 2 interventional study registered as NCT07039526 by John Waters, with 50 participants planned, started 2025-08-19 and due to reach its primary completion in 2027-12. Interventions recorded: CYTALUX™ (pafolacianine) injection preoperatively. Conditions recorded: Esophageal Cancer, Gastrointestinal Cancers, Gynecologic Cancers.
Linked to the drug Pafolacianine because the registry names it among its interventions and Oesophageal cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pafolacianine and the tag pipeline.
Shares Pafolacianine and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/